61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 67-68

61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30

61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30

Background

Women who have undergone thoracic radiation therapy (RT) prior to age 30, for malignancies such as Hodgkin lymphoma (HL), have an approximately 30% risk of breast cancer (BC) by age 50. Screening guidelines for these patients include annual screening mammography (MMG) and breast MRI beginning 8 years after RT but not prior to age 25. The aim of this study was to determine compliance with screening guidelines in these patients who are high risk prior to their BC diagnoses.

Materials and Methods

A retrospective review of a prospectively maintained database was used to identify patients diagnosed with invasive or in situ BC between 2010 and 2021 who had undergone RT for HL prior to age 30. A chart review of the electronic medical record was performed to determine screening adherence prior to the patient’s BC diagnosis.

Results

A total of 6 patients met the inclusion criteria. The mean age at HL diagnosis was 21 (range, 13-26), and the mean age of BC diagnosis was 50 (range, 38-70). The majority of patients were diagnosed with invasive ductal carcinoma (n = 5; 83.3%), and most tumors were high grade (n = 4; 66%). Two patients (33%) had triple-negative BC. Half of the cohort had ductal carcinoma in situ (DCIS) or microinvasive DCIS, while the other half had stage II or III disease. Most patients underwent bilateral mastectomy at the time of their initial cancer diagnosis (n = 5; 83.3%). One patient underwent lumpectomy for their initial cancer diagnosis in 1993 but underwent mastectomies for contralateral BC and an ipsilateral new primary tumor in 2009 and 2012, respectively. No patient began BC screening within 8 to 10 years of thoracic radiation or earlier than age 38. The median time interval between the presumed initiation of BC screening and BC diagnosis was 4 years (range, 0-20). All patients underwent screening MMG, and half had their BC diagnosed with this modality. Only 1 patient had screening breast MRI (16.7%) and 3 patients (50%) had screening breast ultrasound. Most patients were compliant with screening once it began (n = 5; 83.3%); however, 1 patient had an 8-year interval between the MMG that diagnosed her BC and prior screening MMG.

Conclusions

This study found delayed initiation of high-risk BC screening in women diagnosed with BC who had prior thoracic radiation before age 30. Screening breast MRI was also underutilized in this population. This study reveals the importance of educating patients and primary care providers regarding guidelines for the initiation of appropriate BC screening in this high-risk population.

Articles in this issue

41 A Case Series of Sarcomas
41 A Case Series of Sarcomas
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
48 The Era ‘or Error’ of Second Localization Procedures
48 The Era ‘or Error’ of Second Localization Procedures
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table